52-week high: $10.05
Current price: $3.79
Year-to-date performance relative to the Nasdaq Biotechnology Index: Down 53% In Al Mann we distrust. Sure, the billionaire health care entrepreneur used to have the golden touch, but today Mann is old, tired and spending billions on a quixotic quest to develop an inhaled insulin device diabetics neither need nor want. A commercial flop in the making, if it's ever approved.